OncoDxRx Enters Molecular Residual Disease Market with Its Exclusive OncoMRD Test
The precision functional genomics company OncoDxRx unveiled its proprietary OncoMRD assay for monitoring residual disease, an advanced "personalized gene signature” designed for high-precision, simultaneous detection of critical tumor and non-tumor biomarkers.
- (1888PressRelease) November 12, 2024 - This new addition to OncoDxRx’s precision oncology arsenal represents a strategic entry into molecular or measurable residual disease (MRD) market, an area of growing international demand fueled by recent technical advancements. OncoMRD combines innovative gene expression profiling with digital data analytics, offering clinicians a reliable, sensitive solution for detecting tumor signals in dynamic clinical conditions.
The OncoMRD test is designed with a strong focus on accessibility, affordability, and accuracy. Equipped with a high-performance patient-derived gene signature, it can detect, identify, and quantify MRD status in diverse therapeutic conditions. The assay includes a cancer type-specific and customizable panel of biomarkers, allowing for adaptability to other indications, from lung, breast to pancreatic cancer, maximizing test effectiveness.
One of the OncoMRD’s defining characteristics is its high throughput, low cost and quick turnaround. This unique design enhances lab implementation and reduces training and overall workflow by approximately a third of NGS. These features allow OncoMRD to perform rapid, precise measurement, maintaining operational sustainability even at high volumes, and to lift lab readiness.
Designed for rapid deployment, the OncoMRD test can be performed directly on the existing qPCR instruments. OncoMRD’s advanced biomarker algorithms ensure precise detection, providing exceptional accuracy on both tumor and non-tumor (microenvironment) targets.
The OncoMRD test enters the MRD landscape where demand has surged, due to unmet clinical needs. The effectiveness of MRD in solid tumors has underscored their strategic value, leading to an increased interest among diagnostic companies worldwide.
By launching OncoMRD, OncoDxRx seeks to capitalize on this growing demand, positioning OncoMRD as an exclusive and critical asset for clinicians looking to enhance their therapeutic response, disease recurrence monitoring and prognostic capabilities.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam